EP0062

PreclinicalSmall molecule

EP0062 is one of 7 small molecule programs targeting Hormone-receptor-positive Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hormone-Receptor-Positive Breast CancerRecruiting

Hormone-Receptor-Positive Breast CancerPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Hormone-Receptor-Positive Breast Cancer

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Phase 1

1 2

Faslodex

FFresenius Kabi USA, LLC

Phase 1

2 3

Afinitor

Novartis

Preclinical

1 4

Verzenio

Eli Lilly

Preclinical

1 5

Aromasin

Pfizer

Preclinical

1 6

Orserdu

SStemline Therapeutics, Inc.

Preclinical

1 7

EP0062

EEllipses Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Hormone-Receptor-Positive Breast Cancer

NCT05573126

Clinical

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting·EEllipses Pharma·Preclinical·NCT05573126·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EP0062. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP0062 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP0062. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ellipses Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEllipses Pharma

EP0062

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News